Global Brain Tumor Drugs Market Expected to Exceed $3 Billion Through 2022
![PR Newswire](../../../Content/images/providers/PR.png)
CNS Pharmaceuticals, Inc. (CNSP)
Company Research
Source: PR Newswire
PALM BEACH, Florida, Jan. 14, 2020 /PRNewswire/ -- Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. The brain tumor drugs market consist of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain. These drugs are either used alone or in combinations, depending on the type, size and locations of the tumor. The global brain tumor drugs market is expected to grow to $3.41 billion at a CAGR of 9.2% through 2022. This rising popularity of targeted therapies is expected to affect the sales of conventional chemical Brain Tumor drugs, t
Show less
Read more
Impact Snapshot
Event Time:
CNSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNSP alerts
High impacting CNS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CNSP
News
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) was upgraded by analysts at Alliance Global Partners to a "strong-buy" rating.MarketBeat
- CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 [Yahoo! Finance]Yahoo! Finance
- CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024Accesswire
- CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy [Yahoo! Finance]Yahoo! Finance
- CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line TherapyAccesswire
CNSP
Sec Filings
- 1/3/25 - Form 8-K
- 12/11/24 - Form 8-K
- 12/3/24 - Form 8-K
- CNSP's page on the SEC website